MSD
Prevymis (Letermovir)
Biodrugs/ Drugs
Infections
Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT)
2Phase II in Spain,
1Phase I